Biotech Values

[pollyvonwog]

it’s reasonable to assume that the FDA will be less revealing of the methods used by ANDA applicants in light of the CAFC ruling in the Amphastar case.

I agree with your point about MNTA's trade secrets, but I'm not so convinced the FDA will be less revealing. If/when they approve m-copax it will be too quite some fanfare and I'd imagine the FDA will have to be equally as thorough (and revealing) in their reasoning as they were with enox.